[go: up one dir, main page]

PE20091349A1 - Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp - Google Patents

Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp

Info

Publication number
PE20091349A1
PE20091349A1 PE2008001778A PE2008001778A PE20091349A1 PE 20091349 A1 PE20091349 A1 PE 20091349A1 PE 2008001778 A PE2008001778 A PE 2008001778A PE 2008001778 A PE2008001778 A PE 2008001778A PE 20091349 A1 PE20091349 A1 PE 20091349A1
Authority
PE
Peru
Prior art keywords
alkinyl
alkenyl
ring
alkyl
ksp
Prior art date
Application number
PE2008001778A
Other languages
English (en)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Liping Yang
Lalalnthi Dilrukshi Vitharana
Angie R Angeles
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40220231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091349(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20091349A1 publication Critical patent/PE20091349A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN DERIVADO DE TIADIAZOL DE FORMULA (I), DONDE X ES S, S(O), S(O)2; EL ANILLO A QUE INCLUYE E ES UN ANILLO CICLOALQUENILO O HETEROCICLOALQUENILO DE 4 A 8 MIEMBROS; E ES O, S, S(O), S(O)2, C(R4)(R5), ENTRE OTROS; p ES UN ENTERO DE 0 A 4; EL ANILLO B ES UN ANILLO AROMATICO O HETEROAROMATICO, UN ANILLO ALICICLICO PARCIALMENTE INSATURADO, ENTRE OTROS; R1 ES ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R2 ES C(Z)R7, C(Z)OR8, ALQUILO, ENTRE OTROS; R3 ES ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R4 ES H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R5 ES H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R7 ES H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R8 ES H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (a), (b), (c), ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE LA QUINESINA DE LA PROTEINA QUINESINA DEL HUSO (KSP) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS CELULARES
PE2008001778A 2007-10-19 2008-10-16 Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp PE20091349A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98128807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
PE20091349A1 true PE20091349A1 (es) 2009-09-07

Family

ID=40220231

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001778A PE20091349A1 (es) 2007-10-19 2008-10-16 Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp

Country Status (19)

Country Link
US (1) US8796460B2 (es)
EP (1) EP2220061B1 (es)
JP (1) JP5455915B2 (es)
KR (1) KR20100072267A (es)
CN (2) CN101903365B (es)
AR (1) AR068888A1 (es)
AU (1) AU2008312401C1 (es)
BR (1) BRPI0818605A2 (es)
CA (1) CA2702922C (es)
CL (1) CL2008003063A1 (es)
CO (1) CO6321241A2 (es)
ES (1) ES2565983T3 (es)
IL (1) IL205184A0 (es)
MX (1) MX2010004312A (es)
PE (1) PE20091349A1 (es)
RU (1) RU2010119635A (es)
TW (1) TW200934785A (es)
WO (1) WO2009052288A1 (es)
ZA (1) ZA201002701B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
WO2009050236A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
MX2010003346A (es) 2007-10-19 2010-04-09 Boehringer Ingelheim Int Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
WO2009050248A1 (de) * 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Substituierte piperidino-dihydrothienopyrimidine
EP2430030A1 (en) * 2009-05-13 2012-03-21 Schering Corporation Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
US8748626B2 (en) * 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
US20130210733A1 (en) 2010-06-17 2013-08-15 Cytokinetics, Inc. Methods of treating lung disease
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2013033392A1 (en) 2011-08-30 2013-03-07 Wayne State University Therapeutic compounds and methods
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN110041349B (zh) * 2019-05-15 2021-06-01 湖南科技大学 一种含螺二氢嘧啶衍生物及其制备方法和应用
CN111529525A (zh) * 2020-05-15 2020-08-14 淮安市厚沐医疗技术咨询中心 一种Gab1抑制剂用于治疗胆管癌的用途
CN111358786A (zh) * 2020-05-15 2020-07-03 淮安市厚沐医疗技术咨询中心 一种Gab1抑制剂在治疗胆管癌方面的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002354465B2 (en) 2001-12-11 2008-11-20 Fujifilm Corporation Thiadiazoline derivative
CA2478068C (en) 2002-03-08 2011-02-08 Merck & Co., Inc. Dihydropyrazole compounds useful for treating or preventing cancer
JP4377323B2 (ja) 2002-06-14 2009-12-02 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
EP1556052A4 (en) 2002-10-18 2006-11-02 Merck & Co Inc MITOTIC KINESINE HEMMER
WO2004058700A2 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1581497A4 (en) 2002-12-20 2009-03-18 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
US20040192739A1 (en) * 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
AR050920A1 (es) 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2004087050A2 (en) 2003-03-28 2004-10-14 Merck & Co., Inc. Mitotic kinesin inhibitors
ES2377498T3 (es) 2003-04-18 2012-03-28 Kyowa Hakko Kirin Co., Ltd. Inhibidor de quinesina en etapa M
WO2004111023A1 (ja) 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン－１－オキシド誘導体
JP2007501863A (ja) * 2003-06-12 2007-02-01 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
US7329762B2 (en) 2003-06-12 2008-02-12 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
CA2533435A1 (en) 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
US20060234984A1 (en) 2003-08-15 2006-10-19 Coleman Paul J Mitotic kinesin inhibitors
CA2534729A1 (en) 2003-08-15 2005-02-24 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1835756A (zh) 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
AR045342A1 (es) 2003-08-15 2005-10-26 Merck & Co Inc Inhibidores de quinesina mitotica
US20070112044A1 (en) 2003-10-10 2007-05-17 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
WO2005060654A2 (en) * 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1934066A (zh) 2004-03-22 2007-03-21 默克公司 有丝分裂驱动蛋白抑制剂
JP2007533762A (ja) 2004-04-19 2007-11-22 メルク　エンド　カムパニー　インコーポレーテッド ２，２−二置換ピロールの調製方法
DE102004021637A1 (de) 2004-05-03 2005-12-01 Merck Patent Gmbh Dihydrobenzothiophene
DE102004031656A1 (de) 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006007496A2 (en) 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
MXPA06015275A (es) 2004-07-01 2007-03-15 Merck & Co Inc Inhibidores de quinasa mitotica.
CN1980911A (zh) 2004-07-01 2007-06-13 默克公司 有丝分裂驱动蛋白抑制剂
WO2006007497A2 (en) 2004-07-01 2006-01-19 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
EP1773830A1 (en) 2004-07-22 2007-04-18 AstraZeneca AB Fused pyrimidones useful in the treatment and the prevention of cancer
WO2006023083A1 (en) 2004-08-12 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2576168A1 (en) 2004-08-18 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
CN101023086A (zh) 2004-08-18 2007-08-22 阿斯利康(瑞典)有限公司 选择性稠合的杂环及其应用
JP2008510013A (ja) 2004-08-18 2008-04-03 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
EP1791969A4 (en) 2004-09-13 2008-07-02 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
EP1831176A2 (en) 2004-12-21 2007-09-12 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1851213A4 (en) 2005-02-10 2010-10-06 Merck Sharp & Dohme INHIBITORS OF MITOTIC KINESINE
DE102005010000A1 (de) 2005-03-04 2006-09-07 Merck Patent Gmbh Indane
PE20061484A1 (es) 2005-03-09 2007-02-05 Schering Corp Compuestos triciclicos fusionados como inhibidores de la actividad de quinesina de ksp
US20060281778A1 (en) 2005-03-09 2006-12-14 Schering Corporation Compounds for inhibiting KSP Kinesin activity
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
CA2599436A1 (en) 2005-03-16 2006-09-28 Merck & Co., Inc. Mitotic kinesin inhibitors
CN101137372A (zh) 2005-03-16 2008-03-05 默克公司 有丝分裂驱动蛋白抑制剂
JP2008150291A (ja) 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
JP2008137893A (ja) 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
AU2006225636A1 (en) 2005-03-22 2006-09-28 Fujifilm Corporation Therapeutic agent for solid tumor
TW200720265A (en) 2005-03-22 2007-06-01 Kyowa Hakko Kogyo Kk Agent for treatment of hematopoietic tumor
EP1868601A4 (en) 2005-04-07 2008-12-10 Merck & Co Inc MITOTIC KINESINE HEMMER
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
DE102005027170A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102005027168A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102005027169A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
JPWO2006137490A1 (ja) 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
US20080125469A1 (en) 2006-06-09 2008-05-29 Wyeth Thiadiazole compounds and methods of use thereof
US8324257B2 (en) 2006-10-03 2012-12-04 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
AR068890A1 (es) * 2007-11-07 2009-12-16 Schering Corp Compuestos para inhibir la actividad quinesina ksp
JP2011503077A (ja) 2007-11-09 2011-01-27 シェーリング コーポレイション Ｋｓｐキネシン活性を阻害するための化合物
KR20100075508A (ko) * 2007-11-09 2010-07-02 쉐링 코포레이션 Ｋｓｐ 키네신 활성 억제용 화합물
EP2430030A1 (en) * 2009-05-13 2012-03-21 Schering Corporation Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors

Also Published As

Publication number Publication date
CA2702922A1 (en) 2009-04-23
AR068888A1 (es) 2009-12-16
KR20100072267A (ko) 2010-06-30
CN103694258B (zh) 2016-01-13
TW200934785A (en) 2009-08-16
AU2008312401C1 (en) 2014-07-10
WO2009052288A1 (en) 2009-04-23
AU2008312401A1 (en) 2009-04-23
JP2011500714A (ja) 2011-01-06
EP2220061A1 (en) 2010-08-25
ES2565983T3 (es) 2016-04-08
JP5455915B2 (ja) 2014-03-26
US20110123435A1 (en) 2011-05-26
CL2008003063A1 (es) 2010-01-04
CA2702922C (en) 2018-01-16
AU2008312401B2 (en) 2014-03-06
CO6321241A2 (es) 2011-09-20
CN101903365B (zh) 2014-02-05
US8796460B2 (en) 2014-08-05
MX2010004312A (es) 2010-07-05
BRPI0818605A2 (pt) 2015-04-22
EP2220061B1 (en) 2016-02-17
RU2010119635A (ru) 2011-11-27
CN101903365A (zh) 2010-12-01
CN103694258A (zh) 2014-04-02
ZA201002701B (en) 2011-04-28
IL205184A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
ECSP15029636A (es) Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
MX338772B (es) Fungicidas de benceno sustituido.
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
PE20200793A1 (es) Compuestos de cetonas biciclicas sustituidas, como inhibidores de la rip1 cinasa y composiciones farmaceuticas que los comprenden
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
PE20121695A1 (es) 5-alquinil-pirimidinas
PE20150041A1 (es) Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
MX377581B (es) Compuestos antihelmínticos y composiciones y método de uso de los mismos.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PE20091333A1 (es) Compuestos heterociclicos de anillo espiro como moduladores de gamma secretasa
UY28333A1 (es) Inhibidores de caspasa y sus usos.
PE20081850A1 (es) Derivados ciclizados como inhibidores de la eg-5
NZ704627A (en) Spirocyclic isoxazoline parasiticidal combinations
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento

Legal Events

Date Code Title Description
FD Application declared void or lapsed